T1	Participants 569 639	Patients receiving CMV hyperimmune globulin or control immune globulin
T2	Participants 279 412	49 patients were randomized in a multicenter controlled study to receive either CMV-hyperimmune globulin or a control immune globulin
T3	Participants 906 924	Six of 23 patients
T4	Participants 932 945	control group
T5	Participants 984 998	globulin group
